Acute myeloid leukaemia (AML) mortality statistics

Deaths

Deaths from acute myeloid leukaemia, 2017-2019, UK.

Proportion of all deaths

Percentage acute myeloid leukaemia contributes to total cancer deaths, 2017-2019, UK

Age

Peak rate of acute myeloid leukaemia deaths, 2017-2019, UK

 

Trend over time

Change in acute myeloid leukaemia mortality rates since the early 1970s, UK

Acute myeloid leukaemia accounts for 2% of all cancer deaths in the UK (2017-2019).[1-4]

In females in the UK, acute myeloid leukaemia accounts for 1% of all female cancer deaths. In males in the UK, it accounts for 2% of all male cancer deaths).

41% of acute myeloid leukaemia deaths in the UK are in females, and 59% are in males (2017-2019).

Acute myeloid leukaemia mortality rates (European age-standardised Open a glossary item (AS) rates) in the UK are significantly lower in females than in males (2017-2019).

Acute myeloid leukaemia mortality rates (European age-standardised Open a glossary item (AS) rates) for persons are significantly lower than the UK average in Northern Ireland, and similar to the UK average in all other UK constituent countries.

For acute myeloid leukaemia, mortality differences between countries largely reflect differences in incidence.

Acute Myeloid Leukaemia (C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2), Annual Average Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Persons Population, UK, 2017-2019

  England Scotland Wales Northern Ireland UK
Female Deaths 927 96 57 27 1,108
Crude Rate 3.3 3.5 3.6 2.9 3.3
AS Rate 3.2 3.2 3.2 3.1 3.2
AS Rate - 95% LCL 3.1 2.9 2.7 2.4 3.1
AS Rate - 95% UCL 3.3 3.6 3.6 3.7 3.3
Male Deaths 1,328 122 90 30 1,570
Crude Rate 4.8 4.6 5.8 3.2 4.8
AS Rate 5.6 5.2 6.1 4.1 5.5
AS Rate - 95% LCL 5.4 4.7 5.4 3.3 5.4
AS Rate - 95% UCL 5.7 5.8 6.8 5.0 5.7
Persons Deaths 2,255 219 148 57 2,678
Crude Rate 4.0 4.0 4.7 3.0 4.0
AS Rate 4.3 4.1 4.5 3.5 4.2
AS Rate - 95% LCL 4.2 3.8 4.1 3.0 4.2
AS Rate - 95% UCL 4.4 4.4 4.9 4.1 4.3
95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2.

Last reviewed:

Acute myeloid leukaemia mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2017-2019, on average each year more than half of deaths (53%) were in people aged 75 and over.[1-4] This largely reflects higher incidence and lower survival for acute myeloid leukaemia in older people.

Age-specific mortality rates rise steadily from around age 50-54 and more steeply from around age 65-69. The highest rates are in the 85 to 89 age group for both females and males. Mortality rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 75 to 79, when the age-specific mortality rate is 2.1 times lower in females than males.

Acute Myeloid Leukaemia (C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Persons Population, UK, 2017-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, ICD-10 C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2.

Last reviewed:

Acute myeloid leukaemia age-standardised (AS) Open a glossary item rates for females and males combined increased by 55% in the UK between 1971-1973 and 2017-2019.[1-4] The increase was larger in males than in females.

For females, acute myeloid leukaemia AS mortality rates in the UK increased by 36% between 1971-1973 and 2017-2019. For males, acute myeloid leukaemia AS mortality rates in the UK increased by 64% between 1971-1973 and 2017-2019.

Over the last decade in the UK (between 2007-2009 and 2017-2019), acute myeloid leukaemia AS mortality rates for females and males combined remained stable. In females AS mortality rates remained stable, and in males rates remained stable.

Acute Myeloid Leukaemia (C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2), European Age-Standardised Mortality Rates per 100,000 Persons Population, UK, 1971-2019

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Acute myeloid leukaemia mortality rates have varied between age groups in females and males combined in the UK since the early 1970s.[1-4] Rates in 0-24s have decreased by 67%, in 25-49s have decreased by 61%, in 50-59s have decreased by 24%, in 60-69s have increased by 33%, in 70-79s have increased by 121% and in 80+s have increased by 191%.

Acute Myeloid Leukaemia (C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2), European Age-Standardised Mortality Rates per 100,000 Persons Population, By Age, UK, 1971-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 1971-2019, C92.0, C92.4, C92.5, C92.6, C92.8, C93.0, C94.0, C94.2.

Cancers in children and young people (aged 0-24) are best classified using a different system to cancers in adults, so the figures presented here may not correspond with those elsewhere.

Last reviewed:

There is no evidence for an association between acute myeloid leukaemia (AML) mortality and deprivation for either males or females in England.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are similar for both males and females living in the most deprived areas compared with the least deprived.[1]

Acute Myeloid Leukaemia (C92.0,C92.4,C92.5,C93.0,C94.0,C94.2), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in AML mortality between people living in the most and least deprived areas in England has not changed in the period 2002-2011.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: England, 2007-2011, ICD-10 C92.0,C92.4,C92.5,C93.0,C94.0,C94.2

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.